Company profile
ARGENX SE
NASDAQ:ARGXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EFGARTIGIMOD ALFA | approved | — | 7 | approved |
| Adimanebart | phase2 | — | 3 | active |
| Empasiprubart | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (73)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05405361 | phase2 | active_not_recruiting | 2023-01-18 | 2029-09-30 | argenx | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05225675 | phase2 | completed | 2022-03-31 | 2024-06-04 | argenx | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05670704 | phase1 | completed | 2023-02-21 | 2024-08-08 | argenx | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants |
| NCT04225156 | phase3 | completed | 2020-06-02 | 2026-03-11 | argenx | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). |
| NCT05817435 | phase1 | completed | 2023-03-13 | 2023-05-12 | argenx | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761195 | BLA | Argenx BV | ||||
Loading… | ||||||
| BLA 761304 | BLA | Argenx BV | ||||
Loading… | ||||||